Volume 48, Issue 4, Pages (April 2011)

Slides:

Advertisements

Similar presentations

Chapter 85 Chapter 85 Parathyroid Hormone Treatment for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Advertisements

ECTS symposium 5 Anabolic treatment of osteoporosis.

Copyright © 2013 Elsevier Inc. All rights reserved.

TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.

Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Osteoporosis Armed Forces Academy of Medical Sciences.

Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla.

Date of download: 7/6/2016 From: Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial Ann Intern Med. 2015;162(12):

Volume 81, Pages (December 2015)

Volume 44, Issue 5, Pages (May 2009)

Volume 101, Pages (August 2017) Contra-lateral bone loss at the distal radius in postmenopausal women after a distal radius fracture: A two-year.

Silencing miR-106b accelerates osteogenesis of mesenchymal stem cells and rescues against glucocorticoid-induced osteoporosis by targeting BMP2 Ke Liu,

A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP) Frederick S. Kaplan, Mona Al Mukaddam, Robert J.

Copyright © 2005 American Medical Association. All rights reserved.

Volume 354, Issue 9180, Pages (August 1999)

Knee loading stimulates healing of mouse bone wounds in a femur neck

Treatment of ununited femoral neck fractures in young adults using low-intensity pulsed ultrasound: Report of 2 cases Sang Yang Lee, Takahiro Niikura,

Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass P. Dimitri,

Volume 103, Pages (October 2017)

Rafael Fernández Castillo, Maria del Carmen López Ruiz

Bone metabolism in obese rats programmed by early weaning

Volume 64, Pages e1-e3 (January 2017)

Figure 1. Height distribution for adults with AIS.

Goal-directed Treatment for Osteoporosis

Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.

Effects of the Assessment of 4 Determinants of Structural Geometry on QCT- and DXA- Derived Hip Structural Analysis Measurements in Elderly Women Benjamin.

Effects of Exemestane and Tamoxifen Treatment on Bone Texture Analysis Assessed by TBS in Comparison With Bone Mineral Density Assessed by DXA in Women.

Antonia Sophocleous, PhD, Roy Robertson, MD, Nuno B

Ronald D. Emkey, MD, Mark Ettinger, MD

Osteoporosis in Individuals with Spinal Cord Injury

Bone Disease in Patients With Primary Sclerosing Cholangitis

Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis Mirjam Stahl, Christian Holfelder, Carolin.

The independent and combined effects of intensive weight loss and exercise training on bone mineral density in overweight and obese older adults with.

Shannon D. Sullivan, M. D. , Philip M. Sarrel, M. D. , Lawrence M

Bone Mineral Density After Spinal Cord Injury: A Reliable Method for Knee Measurement Richard K. Shields, PhD, PT, Janet Schlechte, MD, Shauna Dudley-Javoroski,

The relationships between bone mineral density in the spine, hip, distal femur and proximal tibia and medial minimum joint space width in the knees of.

The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy Solomon Epstein, MD Mayo.

Osteoporosis in inflammatory bowel disease

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Vert Non-Vert Hip ** ** Zoledronic Acid3 Zoledronic Acid4 Denosumab5

Country-Specific Young Adult Dual-Energy X-Ray Absorptiometry Reference Data Are Warranted for T-Score Calculations in Women: Data From the Peak-25 Cohort

Melissa S. Putman, Joshua F

Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation Sjoerd F. Bakker,

Pediatric Intensive Care Treatment of Uncontrolled Status Epilepticus

Type of Hip Fracture in Patients With Parkinson Disease is Associated With Femoral Bone Mineral Density Marco Di Monaco, MD, Fulvia Vallero, MD, Roberto.

Deborah Givens Heiss, PT, PhD, OCS, Richard K. Shields, PT, PhD, H

Side effects of inhaled corticosteroids

Volume 66, Issue 5, Pages (November 2004)

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain Mohamed A. Bedaiwy,

Chapter 45 Osteoporosis in AdultsPhoto Album

Antibiotic De-Escalation

P. Urena Torres, G. Friedlander, M.C. de Vernejoul, C. Silve, D. Prié

Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome Janet Hegarty, M. Zulf Mughal, Judith.

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Testim® Gel: Review of Clinical Data

Octopus Movement: Push Right, Go Left

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal.

Volume 58, Issue 1, Pages (July 2000)

Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroid-treated asthmatic adults John H. Toogood, MD, FRCPCa,b,

Volume 63, Issue 2, Pages (February 2003)

Interpretation The World Health Organization (WHO) Osteoporosis Guidelines (T Score vs Z score) A Z-score less than –2 indicates the diagnosis is below.

Volume 119, Issue 5, Pages (November 2000)

M. Kathleen Clark, Ph. D. , MaryFran R. Sowers, Ph. D

H.J. Heller, J.E. Zerwekh, F.A. Gottschalk, C.Y.C. Pak

Surgery for Obesity and Related Diseases

Enrollment and Outcomes

Randomized Controlled Trial of Calcium in Healthy Older Women

Volume 57, Issue 2, Pages (October 2000)

Presentation transcript:

Volume 48, Issue 4, Pages 713-719 (April 2011) Time-dependent changes in skeletal response to teriparatide: Escalating vs. constant dose teriparatide (PTH 1–34) in osteoporotic women Elaine W. Yu, Robert M. Neer, Hang Lee, Jason J. Wyland, Amanda V. de la Paz, Melissa C. Davis, Makoto Okazaki, Joel S. Finkelstein Bone Volume 48, Issue 4, Pages 713-719 (April 2011) DOI: 10.1016/j.bone.2010.11.012 Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 1 Recruitment and progression through the study protocol. Bone 2011 48, 713-719DOI: (10.1016/j.bone.2010.11.012) Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 2 In the left column, mean (±SE) serum PINP, OC, and CTX levels in the escalating dose (solid line) and constant dose (dashed line) teriparatide groups over the 18-month study. In the right column, mean % change per 6month time period (±SE) in serum P1NP, OC, and CTX levels in the escalating dose (black bar) and constant dose (open bar) teriparatide groups. In the first 6months, there was a greater increase in P1NP and OC in the constant dose group than in the escalating dose group. In the last 6months, bone markers declined with a negative rate of change in the constant dose group, and remained steady or increased in the escalating dose group. (* indicates p<0.017). Bone 2011 48, 713-719DOI: (10.1016/j.bone.2010.11.012) Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 3 Mean (±SE) percent change in bone mineral density by DXA of the posterior–anterior spine, lateral spine, total hip, femoral neck, distal radius and total body and by QCT of the trabecular lumbar spine in the escalating dose (solid bar) and constant dose (open bar) teriparatide groups. Note that the scale for QCT BMD is different and is marked on the rightward y-axis. There were no significant differences between the two treatment groups at any skeletal site. Bone 2011 48, 713-719DOI: (10.1016/j.bone.2010.11.012) Copyright © 2010 Elsevier Inc. Terms and Conditions